Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
The CTMX news page on Stock Titan aggregates recent coverage and official announcements related to CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company listed on the Nasdaq Global Select Market. CytomX reports that it is developing novel, conditionally activated, masked biologics based on its PROBODY® therapeutic platform, with a focus on cancer indications such as advanced colorectal cancer and advanced melanoma.
Visitors to this page can review news items that describe the progress of CytomX’s clinical programs, including updates on varsetatug masetecan (Varseta-M, formerly CX-2051), a masked EpCAM-directed antibody-drug conjugate with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY® cytokine. Company press releases have discussed Phase 1 dose escalation and expansion activities, translational biomarker data, and plans for potential later-stage development in colorectal cancer and melanoma.
In addition to pipeline updates, CytomX news often includes financial results, business updates, and information about investor conference presentations. These items provide context on the company’s operating priorities, cash position, and interactions with the investment community. News releases also highlight research and collaboration activities involving its PROBODY® platform, such as work on T-cell engagers and cytokine-based approaches in partnership with other biopharmaceutical companies.
By following CTMX news, investors and researchers can monitor how CytomX describes the evolution of its PROBODY® technology, its clinical data disclosures, and its collaborations with partners including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. This page offers a centralized view of publicly released information that may be relevant to understanding the company’s development-stage oncology pipeline and corporate activities.
CytomX (Nasdaq:CTMX) priced an underwritten public offering to raise approximately $250.0 million in gross proceeds by selling 45,990,567 shares of common stock at $5.30 per share and pre-funded warrants for 1,179,245 shares.
The company granted a 30-day option for an additional 7,075,471 shares and expects to close on March 19, 2026. Net proceeds are expected to fund continued development of Varseta-M and other pipeline programs, with remaining proceeds for capital expenditures, working capital and general corporate purposes.
CytomX Therapeutics (NASDAQ:CTMX) has commenced an underwritten public offering of $250.0 million of common stock and, for certain investors, pre-funded warrants, with a 30-day underwriter option to purchase up to an additional $37.5 million. The offering is subject to market and other conditions and may not be completed.
According to the company, net proceeds are expected to fund continued development of Varseta-M and other pipeline programs, with any remaining proceeds for capital expenditures, working capital and general corporate purposes. A shelf registration filed March 16, 2026, became effective upon filing.
CytomX (Nasdaq: CTMX) reported 2025 results and a business update on March 16, 2026. Key items: positive Phase 1 Varseta-M data in advanced colorectal cancer, FDA alignment targeted mid‑2026 for a registrational trial, initiated Varseta-M/bevacizumab combination, and CX‑801 combination data expected by end of 2026.
Financials: $137.1M cash at year‑end with runway to Q2 2027, 2025 revenue $76.2M (down from $138.1M), and 2025 operating expense $98.6M.
CytomX (Nasdaq: CTMX) reported positive Phase 1 expansion data for EpCAM PROBODY ADC varsetatug masetecan in late-line metastatic colorectal cancer. Confirmed ORRs were 32% at 10 mg/kg and 20% at 8.6 mg/kg; estimated median PFS was 7.1 and 6.8 months, respectively. Grade 3 diarrhea was 10% with updated prophylaxis. The company plans FDA interactions in mid-2026 and additional combination and expansion studies through 2026.
CytomX Therapeutics (Nasdaq: CTMX) will report full year 2025 financial results on March 16, 2026, before the open of U.S. markets. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT the same day.
Participants can access the live webcast and archived replay on CytomX's Events and Presentations page and are advised to register at least 10 minutes before the call.
CytomX Therapeutics (Nasdaq: CTMX) announced management will present at two investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on Feb 11, 2026 (fireside chat at 4:30 p.m. ET) and World ADC London on Feb 25, 2026 (presentation at 5:00 p.m. GMT).
Investors can find schedules and webcast details on the company's Events and Presentations page.
CytomX (NASDAQ: CTMX) provided a 2026 business update focused on clinical milestones for its PROBODY pipeline. Varsetatug masetecan (CX-2051) Phase 1 dose expansions (7.2, 8.6, 10 mg/kg Q3W) continue, with total Phase 1 enrollment projected at ~100 patients and a Phase 1 CRC expansion update expected in Q1 2026. The company aims to align with the FDA in 2026 on a potential registrational monotherapy study and plans a Varseta-M plus bevacizumab combination study to start in Q1 2026.
CX-801 (masked interferon-alpha-2b) is in Phase 1 for advanced melanoma; monotherapy reached dose level 4 and combination dose escalation with KEYTRUDA began in May 2025, with initial combo data expected by end of 2026. Management will present at JP Morgan on January 14, 2026.
CytomX Therapeutics (NASDAQ: CTMX) announced management will present at two investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 (fireside chat at 1:45 p.m. ET) in Coral Gables, FL, and the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 (fireside chat at 1:00 p.m. ET) in New York, NY.
A live webcast will be available on the company’s Events and Presentations page at www.cytomx.com, and management will hold one-on-one meetings with registered conference attendees.
CytomX Therapeutics (Nasdaq: CTMX) said Sean McCarthy, D.Phil., chief executive officer and chairman, will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 at 9:00 a.m. GMT.
A live webcast will be available on the company’s Events and Presentations page at www.cytomx.com, and management will be available for one-on-one investor meetings for registered conference attendees.
CytomX Therapeutics (Nasdaq: CTMX) reported Q3 2025 results and a pipeline update on Nov 6, 2025. The company ended Q3 with $143.6 million in cash, cash equivalents and investments and expects runway to Q2 2027. Q3 revenue was $6.0 million versus $33.4 million a year earlier, driven by completion of Bristol Myers Squibb performance obligations and reduced Moderna activity. Operating expense for the quarter was $21.7 million and R&D was $15.3 million.
Pipeline highlights: CX-2051 Phase 1 expansion is ongoing, with projected enrollment of ~100 patients by a planned Phase 1 data update in Q1 2026; a CX-2051 Phase 1b combination with bevacizumab is expected to start in Q1 2026. CX-801 monotherapy biomarker data will be presented at SITC 2025 and supports ongoing combination dosing with KEYTRUDA; combo escalation began in May 2025.